Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome

Pediatric Dermatology

Volumn 22, Issue 3, 2005, Pages 262-265

  Stichweh, Dorothee S ^a   Punaro, Marilynn ^a   Pascual, Virginia ^a,b  

^a TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD2 ANTIGEN; CYCLOSPORIN A; DAPSONE; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TACROLIMUS;

ACNE; ANAMNESIS; ARTHRITIS; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTERITIS; GENE MUTATION; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PAPA SYNDROME; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ACNE VULGARIS; ADOLESCENT; ANTIBODIES, MONOCLONAL; ARTHRITIS; DERMATOLOGIC AGENTS; HUMANS; MALE; PYODERMA GANGRENOSUM; SYNDROME;

EID: 19644375183     PISSN: 07368046     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2005.22320.x     Document Type: Article

References (18)

1. Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST, and are responsible for PAPA syndrome, an autoinflammatory disorder. Human Mol Genet 2002;11:961-969.
2. Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne. PAPA Syndrome Mayo Clinic Proc 1997;72:611-615.
3. Yeon HB, Lindor NM, Seidman JG, et al. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am J Human Genet 2000;66:1443-1448.
4. Wise CA, Bennett LB, Pascual V, et al. Localization of a gene for familial recurrent arthritis. Arthritis Rheumatism 2000;43:2041-2045.
5. Li J, Nishizawa K, An W, et al. A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triagered adhesion. EMBO J 1998;15:7320-7336.
6. Shoham NG, Centola M, Mansfield E, et al. Pyrin binds PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003;100:13501-13506.
7. Badour K, Zhang J, Shi F, et al. The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP 1 adapters to promote formation of the immunological synapse. Immunity 2003;18(1):141-154.
8. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn's disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002;9:1108-1110.
9. Triantafillidis JK, Cheracakis P, Sklavaina M, et al. Favorable response to infliximab treatment in a patient with active Crohn's disease and pyoderma gangrenosum. Scand J Gastroenterol 2002;7:863-865.
10. Arnott IDR, McDonald D, Williams A, et al. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001;15:1639-1646.
11. Grange F, Djilali-Bouzina F, Weiss AM, et al. Corticosteroidresistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology 2002;205:278-280.
12. Tan MH, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001;137:930-933.
13. Botros N, Pickover L, Das KM. Image of the month. Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology 2000;118:654, 809.
14. Sheldon DG, Sawchuk LL, Kozarek RA, et al. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000;135(5):564-569.
15. Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn's disease. J Pediatr Gastroenterol Nutr 2002;34(5):558-560.
16. Ang HTS, Helfgott S. Do clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003;30(11):2315-2318.
17. Shergy WJ, Phillips RM Jr, Hunt RE, et al. Safety and efficacy of infliximab therapy after etanercept failure: a case series. Arthritis Rheum 2001;44(Suppl. 9):S81.
18. Biedermann T, Kneillig M, Mailhammer R, et al. Mast cells control neutrophil recruitment during T cell mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000;192(10):1441-1451.